OneOme to Shutdown, Deal a Blow to PGx Industry Momentum
OneOme, a leading name in pharmacogenomics testing and personalized medicine, has announced that it will cease operations by November 14, 2025, citing ongoing…
-
-
The Three Key Factors Driving the Rise of Preemptive Pharmacogenomics
For years, pharmacogenomics (PGx) was seen as a future promise, a fascinating science that could someday make drug therapy safer and more effective….
-
FDA’s Final Rule on Laboratory-Developed Tests: Implications for Pharmacogenomics
In May 2024, the U.S. Food and Drug Administration (FDA) published a final rule that would bring laboratory-developed tests (LDTs) explicitly under the…
-
APGxA Interview Series: Dr. Gualberto Ruaño, M.D., Ph.D. — Physician Scientist, Innovator, and Entrepreneur
When you talk to Dr. Gualberto Ruaño, you don’t just hear about science — you hear about purpose. A physician, geneticist, and entrepreneur,…
-
The Pharmacogenomics Technology Market: Trends, Insights, and Opportunities
Grand View Research has just released its latest report on the pharmacogenomics technology market, offering fresh insights into one of the fastest-growing areas…
-
How to Navigate FDA Warnings About Unapproved Pharmacogenomic Claims
Pharmacogenetic testing has emerged as one of the most exciting frontiers in personalized medicine. By analyzing a patient’s genetic makeup, these tests promise…
-
What You Should Know About Pharmacogenomic Variant Annotation
The promise of precision medicine lies in its ability to tailor treatments to the genetic makeup of each patient. Pharmacogenomics is central to…
-
Pharmacogenomic Data Submission: Guidelines for Clinicians and Industry Professionals
This blog provides a comprehensive overview of the FDA’s current and draft guidance on pharmacogenomic data submission, highlighting key regulatory requirements, submission algorithms, voluntary submissions, and practical considerations for clinicians and industry professionals.
-
Overcoming Barriers to Implementing PGx Testing in Routine Care
Learn about the barriers to Implementing PGx Testing
-
APGxA Company Spotlight: UGenome AI
UGenome AI is a US based biotech software company developing next-generation tools for genomic data interpretation. Co-founded by CEO Zachary S. Brooks, Chief Strategy Office Peter Bannister, and Chief Genomics Officer Dr. Jayden Lee, PharmD, EMBA, the company specializes in secondary and tertiary genomic analysis—transforming raw sequencing data into actionable, repeatable insights.
End of content
End of content